SARS-CoV-2 Beta variant Spike protein and conserved T cell epitopes (SARS-CoV-2 Beta S/T-cell epitopes)

The SARS-CoV-2 Beta variant (B.1.351) Spike protein is a critical antigen characterized by mutations such as E484K and N501Y, which enhance its ability to evade neutralizing antibodies (NIH, 2021). This protein serves as the primary mediator of viral entry into host cells by binding to the Angiotensin-Converting Enzyme 2 (ACE2) receptor (PubMed, 2021). To address the challenge of viral evolution, therapeutic strategies often combine the variant-specific Spike with conserved T cell epitopes, which are regions of the virus that remain stable across different variants (Nature, 2021). These conserved epitopes, frequently found in the Nucleocapsid (N) and Membrane (M) proteins, are essential for triggering CD4+ and CD8+ T cell responses that provide long-lasting cellular immunity (Cell, 2021). This multi-antigen approach aims to provide broader protection than Spike-only vaccines by ensuring the immune system can recognize the virus even if the Spike protein undergoes significant mutation (Science, 2022). Drugs and vaccines targeting these components work by inducing both humoral and cellular arms of the immune system to prevent infection and severe disease (WHO, 2021).

Other names

B.1.351 Spike proteinSARS-CoV-2 Beta variant S proteinConserved SARS-CoV-2 T-cell antigensBeta variant S-protein with T-cell epitopes

Induction of neutralizing antibodies to block ACE2 binding and activation of CD4+ and CD8+ T cells via conserved epitopes to provide broad cellular immunity.